Profile

DermaSensor Inc. is a health technology company designing non-invasive tools to better equip all physicians for skin cancer detection. The DermaSensor device is an affordable, handheld tool that uses spectroscopy and algorithms to test skin lesions for cancer in seconds. It is currently FDA Cleared, CE Marked, and is available for sale in the U.S.

Visit www.dermasensor.com

Key Products

DermaSensor is the first FDA-cleared automated medical device in the U.S. that provides physicians with an immediate, objective risk assessment for all common skin cancers. DermaSensor employs AI-powered, patented optical spectroscopy technologies to non-invasively detect all common skin cancers at the point of care.

Key Executives

Cody Simmons, Chief Executive Officer

As a bioengineer and entrepreneur, Cody has spent all of his career bringing new health technologies to physicians and patients. He is a frequent speaker at health technology and entrepreneurship events, and Cody was included on the Forbes 30 Under 30 in healthcare. Prior to joining DermaSensor, Cody led commercial efforts for a Silicon Valley medical device screening startup and also worked at Genentech in a leadership development program and commercial strategy roles.

Cody earned undergraduate degrees in economics and bioengineering from Brown University. He also received a Masters of Science in Bioengineering for which he completed his graduate research at Stanford University. During his graduate work at Stanford, he co-founded a laboratory tools startup with two other graduate students, raising an angel round, participating in the StartX program, and completing a licensing deal with Stanford.

Ryan Freiden, Commercial Operations Officer

Ryan has over 20 years of experience founding and scaling companies in consumer goods, healthcare, and enterprise technologies. Recently, Ryan led the growth for a healthcare supply chain technology and previously ran the international manufacturing and distribution of consumer hardware electronics.

Larry Anderson, Chief Commercial Officer

Larry is a West Point Graduate with 20 years of medical device experience, specializing in building teams and launching disruptive technologies. Most recently, Larry led the sales team at Acessa Health to a successful exit to Hologic during the covid-19 pandemic. His previous organizations include Ethicon Women’s Health and Urology, Interlace Medical, Hologic, and BG Medical.

Gary Slatko, Chief Medical Officer

Gary has over 35 years of experience supporting the clinical development, medical affairs, safety surveillance and risk management of biomedical products, including 6 years at FDA. Prior leadership roles include CMO at Aquestive Therapeutics and at ParagonRx, LLC.

Competitors

DermaSensor has no direct competitors in its industry. It is the first FDA-cleared automated medical device in the U.S. that provides physicians with an immediate, objective risk assessment for all three common skin cancers. Utilizing AI-powered, patented optical spectroscopy technologies, DermaSensor non-invasively detects all three common skin cancers at the point of care.

Corporate Responsibility

DermaSensor was developed to address two significant challenges in healthcare: the inability of primary care providers to effectively screen for skin cancer and the prolonged wait times for dermatology appointments.

Firstly, primary care physicians often lack the necessary tools and training to accurately identify skin lesions indicative of cancer. This leads to missed diagnoses, delayed treatment, and poorer outcomes for patients. With melanoma projected to become the second most common cancer by 2040, early detection is crucial.

Secondly, there is a shortage of dermatologists, leading to lengthy appointment wait times. Patients may have to wait weeks or even months before seeing a specialist for a skin examination. This delay can result in anxiety for patients awaiting a diagnosis and can exacerbate the progression of potentially deadly skin conditions.

DermaSensor’s creation represents a breakthrough approach to improving skin care in America by enabling patients with access to early detection and timely management of skin cancer by physicians.